Shanghai Ark Biopharmaceutical Co., Ltd announced today that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for AK0406 injection, the company’s first antiviral drug-Fc …
Decoy Therapeutics Inc, a biotechnology company focused on developing Designable Multi-Antivirals (D-MAVs), has announced that one of its D-MAV candidates has demonstrated in vitro effectiveness against the wild-type Ebola Zaire …
In 2006, Tomas Cihlar was well aware that, despite initial successes with combination therapy, HIV continued to be a global challenge with limited treatment options. At the time, he had …
Carrie Frenette, a veteran liver specialist, reflects on her patients with hepatitis C (HCV) before 2013, the watershed year when the FDA approved Gilead’s groundbreaking medicine, marking the advent of …
